Larimar Therapeutics, Inc. filings document a clinical-stage biotechnology issuer developing nomlabofusp for Friedreich’s ataxia and other potential rare-disease programs using an intracellular delivery platform. Its 8-K reports disclose operating and financial results, FDA-related program updates, corporate presentations, material events and risk language around product development, regulatory review, capital needs and clinical execution.
The company’s SEC record also includes capital-structure and governance disclosures. Filings describe registered common stock on the Nasdaq Global Market, equity financing activity, an exchange involving Series A convertible preferred stock, preferred-stock conversion limitations, shareholder voting matters, executive compensation and board governance through proxy materials.
On September 29, 2026, Larimar Therapeutics, Inc. (LRMR) President and COO John B. Harlow Jr. received 50,000 restricted stock units, each a contingent right to one common share upon settlement, and an option to buy 800,000 common shares at $3.14 per share. The option expires September 29, 2036.
Larimar Therapeutics, Inc. (LRMR) appointed John B. Harlow, Jr. as President and Chief Operating Officer effective September 29, 2026. His employment agreement provides an initial annual base salary of $560,000, subject to annual review and adjustment by the Board’s Compensation Committee, a $35,000 cash signing bonus, and eligibility for a target annual bonus equal to 40% of base salary; the 2026 target is prorated. The actual bonus may be more or less based on corporate and/or personal objectives, and payment generally requires continued employment through the executive bonus payment date, subject to specified involuntary-termination provisions.
Larimar granted an option to purchase 800,000 shares at an exercise price equal to the common stock’s closing price on the effective date, plus restricted stock units covering 50,000 shares. The option vests 25% on the first anniversary of the effective date and the remaining 75% in 36 equal monthly installments; the RSUs vest in four equal annual installments beginning on the first anniversary. Both awards require continued service through applicable vesting dates.
Larimar Therapeutics, Inc. reported a net loss of $32.8 million for the quarter and $62.4 million for the first half of 2026 as it increased investment in nomlabofusp, its lead therapy for Friedreich's ataxia. Quarterly operating expenses rose to $34.4 million, mainly from higher R&D and commercial readiness spending.
Cash, cash equivalents and marketable securities of $156.3 million as of June 30, 2026 are expected to fund operations into the third quarter of 2027; however, management concluded these resources will not cover at least 12 months of planned operations from the reporting date and raised substantial doubt about its ability to continue as a going concern, indicating a need for additional capital.
Nomlabofusp advanced meaningfully: it received FDA Breakthrough Therapy Designation, was selected for the FDA’s START pilot program, and moved into a rolling BLA with the first module submitted in June 2026. Open-label data in 43 patients showed sustained increases in frataxin and directional improvements versus natural history, though 10 participants experienced anaphylaxis and discontinued. A global Phase 3 confirmatory trial is planned to begin dosing in the third quarter of 2026.
Larimar Therapeutics reported second quarter 2026 results and progress for its lead Friedreich’s ataxia program, nomlabofusp. A rolling Biologics License Application seeking accelerated approval is underway after a multidisciplinary FDA pre-BLA meeting in which the agency indicated the existing data package appears capable of supporting submission and reaffirmed its willingness to consider frataxin (FXN) as a novel surrogate endpoint.
Long-term open-label data as of June 2026 showed more than 10,000 doses administered, generally well tolerated with mainly mild-to-moderate injection site reactions, alongside sustained increases in skin FXN levels to ranges seen in asymptomatic carriers and directional improvements in mFARS and other clinical measures versus a FACOMS natural-history cohort. Larimar plans to dose the first patient in a global confirmatory Phase 3 trial in Q3 2026 and targets a potential U.S. launch in mid-2027, if approved. As of June 30, 2026, cash, cash equivalents and marketable securities totaled $156.3 million, with a net loss of $32.8 million for the quarter and projected cash runway into the third quarter of 2027.
Larimar Therapeutics director Thomas Edward Hamilton bought additional common stock in the company. He purchased 50,000 shares in an open-market transaction at a weighted average price of $3.3378 per share, with individual trades ranging from $3.33 to $3.35. Following the purchase, he holds 714,798 common shares directly and 159,433 shares indirectly through Post Edison, LLC.
Larimar Therapeutics has submitted the first module of a rolling Biologics License Application to the FDA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, after Type B pre-BLA meeting minutes indicated the existing data package appears sufficient for submission and that approval will be a matter of review.
The company reported long-term open-label data showing daily nomlabofusp increased skin frataxin (FXN) from a mean 3.7 pg/µg at baseline to 12.1 pg/µg at one year, with 100% of evaluable participants (9/9 at one year; 3/3 at 18 months) reaching FXN levels comparable to asymptomatic carriers. Clinical outcomes also improved, with a 1.0-point mean mFARS improvement at one year and a 2.3-point improvement at 18 months, versus worsening in a FACOMS natural history reference group, yielding 2.6- and 4.6-point advantages respectively. More than 10,000 doses have been given; daily dosing was generally well tolerated, though anaphylaxis occurred in 10 of 41 participants, all of whom recovered after standard treatment. Larimar expects to complete the rolling BLA in the second half of 2026, start dosing in a global confirmatory Phase 3 trial in Q3 2026, and is targeting a potential U.S. launch around mid-2027 if nomlabofusp is approved.
Larimar Therapeutics reported that an entity associated with Deerfield Management received a grant of stock options linked to 55,150 shares of common stock. The options have an exercise price of $3.33 per share and expire on May 19, 2036.
The option was granted to Jonathan S. Leff, who serves on Larimar’s board, but is held for the benefit and at the direction of Deerfield Management Company, L.P. It is scheduled to vest on the earlier of May 19, 2027 or the date of Larimar’s next annual stockholder meeting, subject to Leff’s continued board service. The reporting persons disclaim beneficial ownership beyond any indirect pecuniary interest.
Larimar Therapeutics, Inc. disclosed that an entity associated with director Jonathan S. Leff received a grant of stock options covering 55,150 shares of common stock. The options have an exercise price of $3.33 per share, expire on May 19, 2036, and were granted as compensation.
According to the disclosure, Leff, a partner in Deerfield Management Company, L.P., has no pecuniary interest in these options and disclaims beneficial ownership, holding them for the benefit and at the direction of Deerfield Management Company, L.P. The options vest on the earlier of May 19, 2027 or the company’s next annual stockholder meeting, subject to his continued service on the board.
Larimar Therapeutics director Jeffrey W. Sherman received a grant of 55,150 stock options for common stock. These options carry an exercise price of $3.33 per share and expire on May 19, 2036. They vest on the earlier of May 19, 2027 or the company’s next annual stockholder meeting, subject to his continued board service. This is a compensation-related award rather than an open-market trade, and no common shares were bought or sold in this filing.